Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease

Antonio José Mateo Orobia,1 Jorge Saa,2 Alberto Ollero Lorenzo,3 José María Herreras4,5 1Cornea and Ocular Surface Unit, Aragón Healthcare Research Institute (Instituto de Investigación Sanitaria de Aragón), Miguel Servet University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mateo Orobia AJ, Saa J, Ollero Lorenzo A, Herreras JM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Dry eye disease Artificial tears Hyperosmolarity Osmoprotectants Hyaluronic acid Carmellose Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a4ca39236d824219b01b43dd7f5fe51c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a4ca39236d824219b01b43dd7f5fe51c
record_format	dspace
spelling	oai:doaj.org-article:a4ca39236d824219b01b43dd7f5fe51c2021-12-02T00:42:50ZCombination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease1177-5483https://doaj.org/article/a4ca39236d824219b01b43dd7f5fe51c2018-03-01T00:00:00Zhttps://www.dovepress.com/combination-of-hyaluronic-acid-carmellose-and-osmoprotectants-for-the--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Antonio José Mateo Orobia,1 Jorge Saa,2 Alberto Ollero Lorenzo,3 José María Herreras4,5 1Cornea and Ocular Surface Unit, Aragón Healthcare Research Institute (Instituto de Investigación Sanitaria de Aragón), Miguel Servet University Hospital, Zaragoza, Spain; 2Ophthalmology Department and Research Unit of Jove Hospital Foundation, Gijón, Spain; 3Cornea and Ocular Surface Unit, Meixoeiro Hospital, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain; 4Valladolid University Clinical Hospital, Valladolid, Spain; 5University Institute of Applied Ophthalmobiology (IOBA [Instituto Universitario de Oftalmobiología Aplicada]). Miguel Delibes Campus, Paseo de Belén, Valladolid, Spain Background: Dry Eye Disease (DED) is a multifactorial disease, with a high prevalence, that can have a great impact on the quality of life of patients. The first step of treatment includes the use of lacrimal substitutes composed of polymers, possible to associate osmoprotectant agents to the lacrimal substitutes. The aim of this article is to analyze the properties of the combination of hyaluronic acid (HA), carmellose, and osmoprotectors (Optava Fusion®; Allergan, Inc., Irvine, CA, USA) on DED. General considerations on the use of artificial tears are also proposed.Methods: A group of ophthalmologists, experts in the management of the ocular surface, analyzed different aspects related to DED; among them, the use of artificial tears in general and the properties of the combination of HA, carmellose, and osmoprotectors, in particular, were discussed. A review of the literature was carried out, which included different articles published in Spanish, English, and French until April 2017.Conclusions: DED is a common chronic pathology that usually requires sustained treatment. In addition, the combination of HA, carmellose, and osmoprotectors has proven to be effective in the treatment of symptoms and signs of dry eye by the synergistic action of all its components. This review provides key elements to help ophthalmologists who begin in the management of DED. Keywords: dry eye disease, artificial tears, hyperosmolarity, osmoprotectants, hyaluronic acid, carmelloseMateo Orobia AJSaa JOllero Lorenzo AHerreras JMDove Medical PressarticleDry eye diseaseArtificial tearsHyperosmolarityOsmoprotectantsHyaluronic acidCarmelloseOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 453-461 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dry eye disease Artificial tears Hyperosmolarity Osmoprotectants Hyaluronic acid Carmellose Ophthalmology RE1-994
spellingShingle	Dry eye disease Artificial tears Hyperosmolarity Osmoprotectants Hyaluronic acid Carmellose Ophthalmology RE1-994 Mateo Orobia AJ Saa J Ollero Lorenzo A Herreras JM Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
description	Antonio José Mateo Orobia,1 Jorge Saa,2 Alberto Ollero Lorenzo,3 José María Herreras4,5 1Cornea and Ocular Surface Unit, Aragón Healthcare Research Institute (Instituto de Investigación Sanitaria de Aragón), Miguel Servet University Hospital, Zaragoza, Spain; 2Ophthalmology Department and Research Unit of Jove Hospital Foundation, Gijón, Spain; 3Cornea and Ocular Surface Unit, Meixoeiro Hospital, Complejo Hospitalario Universitario de Vigo (CHUVI), Vigo, Spain; 4Valladolid University Clinical Hospital, Valladolid, Spain; 5University Institute of Applied Ophthalmobiology (IOBA [Instituto Universitario de Oftalmobiología Aplicada]). Miguel Delibes Campus, Paseo de Belén, Valladolid, Spain Background: Dry Eye Disease (DED) is a multifactorial disease, with a high prevalence, that can have a great impact on the quality of life of patients. The first step of treatment includes the use of lacrimal substitutes composed of polymers, possible to associate osmoprotectant agents to the lacrimal substitutes. The aim of this article is to analyze the properties of the combination of hyaluronic acid (HA), carmellose, and osmoprotectors (Optava Fusion®; Allergan, Inc., Irvine, CA, USA) on DED. General considerations on the use of artificial tears are also proposed.Methods: A group of ophthalmologists, experts in the management of the ocular surface, analyzed different aspects related to DED; among them, the use of artificial tears in general and the properties of the combination of HA, carmellose, and osmoprotectors, in particular, were discussed. A review of the literature was carried out, which included different articles published in Spanish, English, and French until April 2017.Conclusions: DED is a common chronic pathology that usually requires sustained treatment. In addition, the combination of HA, carmellose, and osmoprotectors has proven to be effective in the treatment of symptoms and signs of dry eye by the synergistic action of all its components. This review provides key elements to help ophthalmologists who begin in the management of DED. Keywords: dry eye disease, artificial tears, hyperosmolarity, osmoprotectants, hyaluronic acid, carmellose
format	article
author	Mateo Orobia AJ Saa J Ollero Lorenzo A Herreras JM
author_facet	Mateo Orobia AJ Saa J Ollero Lorenzo A Herreras JM
author_sort	Mateo Orobia AJ
title	Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
title_short	Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
title_full	Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
title_fullStr	Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
title_full_unstemmed	Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
title_sort	combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a4ca39236d824219b01b43dd7f5fe51c
work_keys_str_mv	AT mateoorobiaaj combinationofhyaluronicacidcarmelloseandosmoprotectantsforthetreatmentofdryeyedisease AT saaj combinationofhyaluronicacidcarmelloseandosmoprotectantsforthetreatmentofdryeyedisease AT ollerolorenzoa combinationofhyaluronicacidcarmelloseandosmoprotectantsforthetreatmentofdryeyedisease AT herrerasjm combinationofhyaluronicacidcarmelloseandosmoprotectantsforthetreatmentofdryeyedisease
_version_	1718403516585738240

Combination of hyaluronic acid, carmellose, and osmoprotectants for the treatment of dry eye disease

Ejemplares similares